Alirocumab: an investigational treatment for hypercholesterolemia

Abstract

Click to increase image sizeClick to decrease image size Additional informationNotes on contributorsKausik K RayKausik Kumar Ray is visiting Professor of Cardiovascular Disease Prevention in the Division of Cardiovascular Sciences, University of London, London, UK. Professor Ray received his medical education (MB ChB, 1991) at the University of Birmingham Medical School, UK, his MD (2004) at the University of Sheffield, UK, a postdoctoral fellowship at Harvard Medical School, Massachusetts, USA, and finally an MPhil in Epidemiology (2007) from the University of Cambridge, UK. A Fellow of the American College of Cardiology, the European Society of Cardiology, the American Heart Association and the Royal College of Physicians, Professor Ray is also a member of the British Cardiovascular Society. Professor Ray has been the national lead investigator, served on the committees or been Principal Investigator for several major medical trials, including T-EMERGE 8, SOLID TIMI 52, SAVOR TIMI 54, DAL OUTCOMES II, DAL-ACUTE, ODYSSEY and DECLARE TIMI 58. Professor Ray’s research interests have focused on the prevention and reduction of coronary events. He has investigated the early benefits of statin therapy, the advantages of more/less intensive glycaemic control, and the risks/benefits of aspirin therapy. He continues to investigate the role of lipids, lipoproteins, diabetes, inflammation and thrombosis in recurrent coronary events. He has received numerous research grants including from the British Heart Foundation and the Wellcome Trust Project. At St George’s University of London he developed the Integrated Care Pathway for patients with ACS.